Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio

New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to be ...
Kalkine Media

Masimo Corporation (NASDAQ:MASI) Nasdaq Composite Signals MedTech Focus

Masimo (NASDAQ:MASI) supports medical monitoring innovation as nasdaq composite discussions include healthcare technology ...

Predictmedix AI Inc.: Predictmedix AI Inc. Announces Proposed Name Change to QScreen AI Inc., Pioneering the Fusion of Quantum Computing and AI to Transform Healthcare

Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), excited to announce its proposed name change ...